Skip to main content

Table 3 Current and lifetime substance use of the overall study sample and by smoking status

From: Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial

Characteristic

Overall (N = 150)

%/M ± SD/ Md (Q1, Q3)

Smokers (n = 126)

n(%)/M ± SD/ Md (Q1, Q3)

Non-smokers (n = 24)

n(%)/M ± SD/ Md (Q1, Q3)

p

Urine drug screen

 Any drug

74(49.3)

65(51.6)

9(37.5)

.20

 Opiates

37(24.7)

32(25.4)

5(20.8)

.63

 Cocaine

44(29.5)

41(32.5)

3(12.5)

.04

 Benzodiazepines

23(15.3)

19(15.1)

4(16.7)

.76

 Amphetamines

17(11.3)

14(11.1)

3(12.5)

.73

Alcohol and drug use

 Past 30 days use

 Alcohol

47(31.3)

44(34.9)

3(12.5)

.02

 Alcohol intoxication

36(24.0)

36(28.5)

0(0.0)

.002

 Cannabis

44(29.3)

38(30.1)

6(25)

.61

 Methadone

148(98.6)

124(98.4)

24(100)

.53

 Opiates

33(22.0)

28(22.2)

5(20.8)

.88

 Cocaine

36(24.0)

35(27.7)

1(4.1)

.01

 Barbiturates

6(4.0)

4(3.1)

2(8.3)

.23

 Hallucinogens

5(3.3)

5(3.9)

0(0)

.32

 Inhalants

1(0.6)

1(0.7)

0(0)

.66

 Lifetime use (years)

 Alcohol

2(0, 7)

2(0, 9.75)

0(0, 3.7)

.11

 Alcohol intoxication

1(0, 6.7)

1.5(0 7.0)

0(0, 2)

.04

 Cannabis

3.5(0, 15)

4.5(0, 15)

0(0, 22.5)

.80

 Methadone

8(3, 12.7)

7(2.25, 15)

10.5(5.25, 23.5)

.08

 Opiates

1(0, 5)

1(0, 5)

2(0, 7)

.50

 Cocaine

4.5(0, 14.5)

5(0, 15)

2(0, 8.5)

.19

 Barbiturates

0(0, 0)

0(0, 0)

0(0, 0)

.07

 Hallucinogens

0(0, 1)

0(0, 1)

0(0, 0.25)

.87

 Inhalants

0(0, 0)

0(0, 0)

0(0, 0)

.19

  1. Note: M mean, SD standard deviation, Md median, Q1 quartile 1, Q3 quartile 3